Printer Friendly

FDA Places Advaxis Phase 1/2 Combination Study of Axalimogene Filolisbac with Imfinzi on Clinical Hold.

M2 PHARMA-March 13, 2018-FDA Places Advaxis Phase 1/2 Combination Study of Axalimogene Filolisbac with Imfinzi on Clinical Hold

(C)2018 M2 COMMUNICATIONS

- The US Food and Drug Administration has notified Princeton New Jersey-based immunotherapy developer Advaxis, Inc. (NASDAQ: ADXS) that its investigational new drug application for its Phase 1/2 combination study of axalimogene filolisbac with Imfinzi (durvalumab) for the treatment of patients with advanced, recurrent, or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer was placed on clinical hold, the company said.

The clinical hold pertains to a recent submission of a safety report to the FDA regarding a Grade 5 Serious Adverse Event (patient death) on February 27, 2018 involving respiratory failure which occurred following the sixth combination cycle in the trial.

Enrollment and further dosing are on hold in this trial while the company, its partner and the FDA work closely with the site investigator to review this event in detail and to resolve this clinical hold.

Enrollment and dosing in all other Advaxis clinical programmes are unaffected at this time.

Advaxis is focused on the discovery, development, and commercialization of proprietary Lm-based antigen delivery products based on a platform technology that utilises live attenuated Listeria monocytogenes bioengineered to secrete antigen/adjuvant fusion proteins.

These Lm-based strains integrate multiple functions into a single immunotherapy.

The company has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 13, 2018
Words:257
Previous Article:llumina Appoints Dr. Phil Febbo as CMO.
Next Article:EMA Validates Emmaus' MAA for Xyndari (oral glutamine) Sickle Cell Disease Treatment.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters